Skip to main content
Industry News
Blood biomarkers tied to Alzheimer's progression

Researchers associated increased blood p-tau181 levels with cognitive decline and neurodegeneration in Alzheimer's disease-characteristic brain areas among individuals with elevated amyloid-beta levels, while higher plasma neurofilament light chain levels correlated with cognitive impairment and neurodegeneration among those with and without amyloid-beta accumulation, researchers reported in JAMA Neurology. The study "is a major step forward showing that blood tests for tau pathology and neurodegeneration have clinical value to track disease progression in patients with Alzheimer's disease," said researcher Dr. Kaj Blennow.

Full Story: